Sagimet's Partner Reports 52-Week Acne Trial Data at Dermatology Conference
Ascletis presented results from Phase 3 extension study of denifanstat, a FASN inhibitor licensed to Sagimet outside China.
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced that positive 52-week clinical results from a Phase 3 open-label extension trial will be presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada, taking place October 8-11. The trial evaluated denifanstat in patients with moderate to severe acne vulgaris and was conducted by the company's license partner, Ascletis BioScience Co. Ltd., in China.
Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor. Ascletis is developing the compound as ASC40 under an exclusive license in China, while Sagimet holds development and commercialization rights in the rest of the world. The trial, identified as ASC40-304, represents the extended follow-up phase of the company's dermatology program.
Sagimet, a clinical-stage biopharmaceutical company, focuses on developing therapeutics targeting dysfunctional metabolic and fibrotic pathways. The presentation of mechanistic data alongside the 52-week efficacy results will provide insight into the drug's mechanism of action in treating acne. The conference presentation marks a significant data readout for the FASN inhibitor program and signals progress in the company's pipeline expansion.
The licensing arrangement between Sagimet and Ascletis represents a territorial split common in global drug development, allowing both parties to advance the compound in their respective geographies. The positive results from the extended study could inform next steps for denifanstat's development trajectory in markets outside China. Results of this magnitude at a major dermatology conference typically influence market perception and competitive positioning for emerging acne therapeutics.